Drug intelligence / Profile preview

kanitinib

Development stage: Phase 1
Modality: Small Molecules

Overview

Kanitinib (CX1003) is a novel multi-target tyrosine kinase inhibitor. It is primarily designed to inhibit vascular endothelial growth factor receptor 2 (VEGFR2) and hepatocyte growth factor receptor (HGFR/MET). The drug is being evaluated for its safety, pharmacokinetics, and antitumor activity in patients with advanced or metastatic solid tumors.

Other names: Kanitinib

Targets

MET (Mesenchymal-epithelial transition factor receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR4 (Vascular endothelial growth factor Receptor-3)ABCG2 (ATP-binding cassette sub-family G member 2)ABCB1 (P-glycoprotein)VEGFR-1 (Vascular endothelial growth factor receptor 1)

Beyond the preview

Go deeper on kanitinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on kanitinib.

Explore the full profile